Key result
Osimertinib retreatment at reduced doses induced Takotsubo syndrome in an 81-year-old female patient with lung adenocarcinoma and no prior cardiac history.
Why the study?
The cardiotoxicity of osimertinib, an EGFR-tyrosine kinase inhibitor, has been recently reported when treating EGFR mutation-positive non-small cell lung cancer.
Does osimertinib induce Takotsubo syndrome in patients with lung adenocarcinoma?
Case Report (n=1)
Does osimertinib induce Takotsubo syndrome in patients with lung adenocarcinoma?
Osimertinib treatment for lung adenocarcinoma may induce Takotsubo syndrome, highlighting the need for clinical vigilance for cardiotoxicity.
Answers are grounded in this paper and cite their sources.
May signal osimertinib-associated Takotsubo risk in lung adenocarcinoma; hypothesis-generating case report requiring prospective confirmation.
The cardiotoxicity of osimertinib, an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, has been recently reported when treating EGFR mutation-positive non-small cell lung cancer. In this report, we describe a case of an 81-year-old female patient diagnosed with Takotsubo syndrome (TTS). TTS occurred despite the patient receiving osimertinib retreatment at reduced doses and having no history of cardiac or respiratory disease. The findings of this case suggest that clinicians should consider the possibility of TTS induced by osimertinib.
No takes yet. Share an insight, caveat, or question.
Okamoto et al. (2024) conducted a case report in Lung adenocarcinoma (n=1). Osimertinib was evaluated on Takotsubo syndrome. Osimertinib retreatment at reduced doses induced Takotsubo syndrome in an 81-year-old female patient with lung adenocarcinoma and no prior cardiac history.
Synapse has enriched 10 related papers. Consider them for comparative context: